January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 
January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 

Pipeline One Icon Pipeline One Header 

Cambridge Healthtech Institute’s 3rd Annual
Enhancing Antibody Binding and Specificity
Scientific Strategies for Measuring and Engineering Target-Specific Binding and Specificity
for Next-Generation Antibody Therapeutics

January 19-20, 2016

As the industry expands its repertoire of antibody-drug products into new therapeutic areas, product formats and protein constructs, the control of antibody/antigen targeting, binding and specificity will take on a new level of importance for researchers in this field. The Enhancing Antibody Binding and Specificity conference presents innovative approaches to the modulation of binding activity, mechanism of action and difficult target challenges such as transmembrane proteins and intracellular targeting.

Preliminary Agenda 

New Methods and Antibody Formats for Achieving Exceptional Specificity

Shohei Koide, Ph.D., Professor, Biochemistry and Molecular Biology, University of Chicago


Talk Title to be Announced

Caroline Colley, Ph.D., Senior Scientist, Antibody Discovery and Protein Engineering, MedImmune

New Advances in High-Throughput Epitope Binning

Yasmina Abdiche, Ph.D., Research Fellow, Rinat-Pfizer

Talk Title to be Announced

Alexander Ivanov, Ph.D., Senior Scientist, AbbVie Bioresearch Center


Biologic and Antibody Approaches to Undruggable Intracellular Targets

David A. Scheinberg, M.D., Ph.D., Vincent Astor Chair and Chairman, Molecular Pharmacology Program, Sloan Kettering Institute

Targeting Cell Surface Antigens with a Novel Therapeutic Antibody Concept

Paul W.H.I. Parren, Ph.D., Senior Vice President and Scientific Director, Genmab

Novel Insights of Engineering Non-Antigen Contact Regions of Factor VIII Mimetic Bispecific Anti-Factor IXa/Factor X IgG Antibody

Yuri Teranishi, Researcher, Antibody Engineering Group, Discovery Research, Chugai Pharmaceutical Co., Ltd.

Antibody Engineering for Enhanced Ph-Dependent FcRn Interaction

Tilman Schlothauer, Ph.D., Senior Scientist, Biochemical and Analytical Research, Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center Penzberg

Insights into the Molecular Basis of a Bispecific Antibody’s Target Selectivity

Yariv Mazor, Ph.D., Scientist, Antibody Discovery and Protein Engineering, MedImmune


Antibody Discovery against GPCRs Using Yeast Antibody Display Technology

Abhishek Datta, Ph.D., Scientist II, Drug Discovery, Biogen

Engineering Ion Channels for Structural Studies and Ligand Discovery

Susmith Mukund, Senior Research Associate, Genentech, Inc.

Antibody-Mediated Blockade of Human Orai1 Inhibits T Cell Activation in vitro and in vivo 

Stefan Zahn, Ph.D., Principal Scientist, Antibody Technology, Novo Nordisk A/S

Targeting Tumor-Specific Cell Surface Antigens

Madan Katragadda, Ph.D., Senior Principal Scientist, Pfizer

Challenges in Generating Antibodies to Integral Membrane Proteins

Ramkrishna (Ramu) Sadhukhan, Senior Group Leader, AbbVie Bioresearch Center

For questions about the meeting, please contact: 

For partnering & sponsorship information, please contact: 

Kent Simmons
Senior Conference Director
Cambridge Healthtech Institute
Phone: 207-869-9199
Email: ksimmons@healthtech.com 

Companies A-K
Jason Gerardi
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Fax: 781-972-5470
Email: jgerardi@healthtech.com 

Companies L-Z
Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5471
Fax: 781-972-5470
Email: dinerstein@healthtech.com